Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar
Polpharma Biologics will retain full responsibility for developing and manufacturing the biosimilar candidate.
Drug Development
Apertura and NIH institutes to test gene therapy for NPC1
Sino and AstraZeneca sign licence agreement for TQC3721
Evogene and Tel Aviv University launch drug discovery initiative
FDA grants rare paediatric designation to Vanda’s CMT2S therapy
Biocytogen and Whitehawk partner to develop ADCs
Vertex signs agreement to acquire Crinetics for $10bn
EC approves AbbVie’s Tepkinly combination for follicular lymphoma
